255 related articles for article (PubMed ID: 22559235)
1. Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
Mannelqvist M; Stefansson IM; Wik E; Kusonmano K; Raeder MB; Øyan AM; Kalland KH; Moses MA; Salvesen HB; Akslen LA
BMC Cancer; 2012 May; 12():169. PubMed ID: 22559235
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.
Mongre RK; Sodhi SS; Sharma N; Ghosh M; Kim JH; Kim N; Park YH; Shin YG; Kim SJ; Jiao ZJ; Huynh do L; Jeong DK
Int J Oncol; 2016 Jan; 48(1):84-98. PubMed ID: 26573874
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of a specific receptor for lipocalin2 (solute carrier family 22 member 17, SLC22A17) and its prognostic significance in endometrial carcinoma.
Miyamoto T; Asaka R; Suzuki A; Takatsu A; Kashima H; Shiozawa T
Exp Mol Pathol; 2011 Oct; 91(2):563-8. PubMed ID: 21763306
[TBL] [Abstract][Full Text] [Related]
5. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
[TBL] [Abstract][Full Text] [Related]
7. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.
Mahadevan NR; Rodvold J; Almanza G; Pérez AF; Wheeler MC; Zanetti M
BMC Cancer; 2011 Jun; 11():229. PubMed ID: 21649922
[TBL] [Abstract][Full Text] [Related]
8. Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer.
Cho H; Kim JH
J Histochem Cytochem; 2009 May; 57(5):513-21. PubMed ID: 19188485
[TBL] [Abstract][Full Text] [Related]
9. Lipocalin-2 and matrix metalloproteinase-9 expression in high-grade endometrial cancer and their prognostic value.
Srdelić Mihalj S; Kuzmić-Prusac I; Zekić-Tomaš S; Šamija-Projić I; Čapkun V
Histopathology; 2015 Aug; 67(2):206-15. PubMed ID: 25522256
[TBL] [Abstract][Full Text] [Related]
10. Lipocalin 2 promotes breast cancer progression.
Yang J; Bielenberg DR; Rodig SJ; Doiron R; Clifton MC; Kung AL; Strong RK; Zurakowski D; Moses MA
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3913-8. PubMed ID: 19237579
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.
Kurozumi S; Alsaeed S; Orah N; Miligy IM; Joseph C; Aljohani A; Toss MS; Fujii T; Shirabe K; Green AR; Aleskandarany MA; Rakha EA
Breast Cancer Res Treat; 2020 Feb; 179(3):557-564. PubMed ID: 31707510
[TBL] [Abstract][Full Text] [Related]
12. LCN2 Promoter Methylation Status as Novel Predictive Marker for Microvessel Density and Aggressive Tumor Phenotype in Breast Cancer Patients.
Meka Pb; Jarjapu S; Nanchari SR; Vishwakarma SK; Edathara PM; Gorre M; Cingeetham A; Vuree S; Annamaneni S; Dunna NR; Mukta S; B T; Satti V
Asian Pac J Cancer Prev; 2015; 16(12):4965-9. PubMed ID: 26163623
[TBL] [Abstract][Full Text] [Related]
13. The induction of lipocalin-2 protein expression in vivo and in vitro.
Zhao P; Elks CM; Stephens JM
J Biol Chem; 2014 Feb; 289(9):5960-9. PubMed ID: 24391115
[TBL] [Abstract][Full Text] [Related]
14. Nodal metastasis and survival in oral cancer: Association with protein expression of SLPI, not with LCN2, TACSTD2, or THBS2.
Noorlag R; van der Groep P; Leusink FK; van Hooff SR; Frank MH; Willems SM; van Es RJ
Head Neck; 2015 Aug; 37(8):1130-6. PubMed ID: 24764155
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of platelet-derived growth factor-D as a poor prognosticator in endometrial cancer.
Ding J; Li XM; Liu SL; Zhang Y; Li T
Asian Pac J Cancer Prev; 2014; 15(8):3741-5. PubMed ID: 24870786
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer.
Tanaka Y; Terai Y; Kawaguchi H; Fujiwara S; Yoo S; Tsunetoh S; Takai M; Kanemura M; Tanabe A; Ohmichi M
Cancer Biol Ther; 2013 Jan; 14(1):13-9. PubMed ID: 23114646
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells.
Tung MC; Hsieh SC; Yang SF; Cheng CW; Tsai RT; Wang SC; Huang MH; Hsieh YH
Prostate; 2013 Sep; 73(12):1281-90. PubMed ID: 23775308
[TBL] [Abstract][Full Text] [Related]
18. Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer.
Xu B; Jin DY; Lou WH; Wang DS
World J Surg; 2013 Aug; 37(8):1892-900. PubMed ID: 23539193
[TBL] [Abstract][Full Text] [Related]
19. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta.
Karlsen JR; Borregaard N; Cowland JB
J Biol Chem; 2010 May; 285(19):14088-100. PubMed ID: 20220144
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.
Bauer M; Eickhoff JC; Gould MN; Mundhenke C; Maass N; Friedl A
Breast Cancer Res Treat; 2008 Apr; 108(3):389-97. PubMed ID: 17554627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
